Form 8-K - Current report:
SEC Accession No. 0001641172-25-003034
Filing Date
2025-04-07
Accepted
2025-04-07 17:26:16
Documents
15
Period of Report
2025-04-04
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43559
2 ex16-1.htm EX-16.1 896
3 ex16-1_001.jpg GRAPHIC 162962
  Complete submission text file 0001641172-25-003034.txt   448170

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE zvsa-20250404.xsd EX-101.SCH 3012
5 XBRL LABEL FILE zvsa-20250404_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE zvsa-20250404_pre.xml EX-101.PRE 24163
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3815
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

EIN.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41184 | Film No.: 25819112
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)